IL75400A - Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same - Google Patents

Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same

Info

Publication number
IL75400A
IL75400A IL75400A IL7540085A IL75400A IL 75400 A IL75400 A IL 75400A IL 75400 A IL75400 A IL 75400A IL 7540085 A IL7540085 A IL 7540085A IL 75400 A IL75400 A IL 75400A
Authority
IL
Israel
Prior art keywords
dialkoxypyridine
benzimidazoles
sulfinyl
sulfonyl
methyl
Prior art date
Application number
IL75400A
Other languages
English (en)
Other versions
IL75400A0 (en
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25691679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL75400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of IL75400A0 publication Critical patent/IL75400A0/xx
Publication of IL75400A publication Critical patent/IL75400A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/52—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL75400A 1984-06-16 1985-06-04 Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same IL75400A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH289984 1984-06-16
CH290184 1984-06-16

Publications (2)

Publication Number Publication Date
IL75400A0 IL75400A0 (en) 1985-10-31
IL75400A true IL75400A (en) 1988-10-31

Family

ID=25691679

Family Applications (1)

Application Number Title Priority Date Filing Date
IL75400A IL75400A (en) 1984-06-16 1985-06-04 Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same

Country Status (22)

Country Link
US (1) US4758579A (cg-RX-API-DMAC7.html)
EP (1) EP0166287B1 (cg-RX-API-DMAC7.html)
AU (1) AU578703B2 (cg-RX-API-DMAC7.html)
BG (1) BG61322B2 (cg-RX-API-DMAC7.html)
CA (1) CA1254215A (cg-RX-API-DMAC7.html)
CY (1) CY1670A (cg-RX-API-DMAC7.html)
CZ (1) CZ281242B6 (cg-RX-API-DMAC7.html)
DE (2) DE19475025I2 (cg-RX-API-DMAC7.html)
DK (1) DK170440B1 (cg-RX-API-DMAC7.html)
ES (1) ES8705875A1 (cg-RX-API-DMAC7.html)
GR (1) GR851399B (cg-RX-API-DMAC7.html)
HK (1) HK86894A (cg-RX-API-DMAC7.html)
IE (1) IE58117B1 (cg-RX-API-DMAC7.html)
IL (1) IL75400A (cg-RX-API-DMAC7.html)
LU (1) LU88700I2 (cg-RX-API-DMAC7.html)
MY (1) MY103021A (cg-RX-API-DMAC7.html)
NL (1) NL950030I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ212415A (cg-RX-API-DMAC7.html)
PH (2) PH21850A (cg-RX-API-DMAC7.html)
PT (1) PT80641B (cg-RX-API-DMAC7.html)
SG (1) SG80192G (cg-RX-API-DMAC7.html)
SK (1) SK278401B6 (cg-RX-API-DMAC7.html)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW4585A1 (en) * 1984-04-19 1985-11-20 Hoffmann La Roche Imidazole derivatives
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
NZ220022A (en) * 1986-04-22 1990-04-26 Byk Gulden Lomberg Chem Fab 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3621215A1 (de) * 1986-06-25 1988-01-07 Bayer Ag Fluorhaltige o-phenylendiamine und o-aminophenole
KR890701585A (ko) * 1987-07-16 1989-12-21 헤르베르크 슈키·울리히 볼프 새로운 디아졸
AU2817989A (en) * 1987-12-11 1989-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel benzimidazole derivatives
DE4018642C2 (de) * 1990-06-11 1993-11-25 Byk Gulden Lomberg Chem Fab Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
FR2665158B1 (fr) * 1990-07-30 1993-12-24 Air Liquide Clathrates de peroxyacides.
EP0481764B1 (en) * 1990-10-17 2000-03-29 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
EP0649305A1 (en) * 1992-07-08 1995-04-26 Monsanto Company Benzimidazoles for alleviating stomach ulcers in swine
CA2161256C (en) * 1993-04-27 2004-06-29 Nancy M. Gray Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
JPH08509738A (ja) * 1993-04-27 1996-10-15 セプラコー，インコーポレイテッド 光学的に純粋な（＋）パントプラゾールを用いる胃の疾患治療の方法と組成
AU4504000A (en) * 1993-04-27 2000-09-07 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
TW280770B (cg-RX-API-DMAC7.html) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
CN1045773C (zh) * 1994-06-23 1999-10-20 沈阳药科大学 吡啶衍生物的制备方法
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
WO1997012581A2 (en) * 1995-09-21 1997-04-10 Pharma Pass L.L.C. Novel composition containing an acid-labile omeprazole and process for its preparation
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6599927B2 (en) 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
JP2002510293A (ja) * 1997-05-30 2002-04-02 ドクター・レディーズ・リサーチ・ファウンデーション 抗潰瘍剤として新規なベンゾイミダゾール誘導体、それらの製造方法、及びそれらを含有する薬学的組成物
DE19745692A1 (de) * 1997-07-24 1999-01-28 Bayer Ag Verfahren zur Herstellung von 2-Chlor-benzimidazol-Derivaten
AU9067198A (en) 1997-07-25 1999-02-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6328994B1 (en) 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
WO2000000474A1 (en) * 1998-06-26 2000-01-06 Russinsky Limited Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds
KR100472126B1 (ko) 1998-08-10 2005-03-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 양성자 펌프 억제제의 프로드러그
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
DK1105105T3 (da) 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
BR0011347A (pt) 1999-06-07 2002-03-19 Byk Gulden Lomberg Chem Fab Preparações e formas de administração compreendendo um composto ativo de ácido instável
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
ES2185459B1 (es) 2000-10-02 2003-12-16 Dinamite Dipharma Spa Procedimiento para la obtencion de pantoprazol y compuestos intermedios para el mismo.
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
SI1341524T1 (sl) 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
US7357943B2 (en) 2000-12-07 2008-04-15 Nycomed Gmbh Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
WO2002080762A1 (en) * 2001-04-06 2002-10-17 Medic4All Inc. A physiological monitoring system for a computational device of a human subject
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
JP4020076B2 (ja) * 2001-09-18 2007-12-12 ゼリア新薬工業株式会社 ベンズイミダゾール誘導体
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
MXPA04009979A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxicilina.
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
SI1578742T1 (sl) 2002-12-06 2013-02-28 Takeda Gmbh Postopek za pripravo optično čistih aktivnih spojin
WO2004052881A2 (en) 2002-12-06 2004-06-24 Altana Pharma Ag Process for preparing (s)-pantoprazole
EP1572680A2 (en) 2002-12-19 2005-09-14 Eva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, known pantoprazole sodium hydrates, processes for their preparation.
CA2513555C (en) * 2003-01-15 2012-09-11 Cipla Limited Process for the preparation of pyridylsulfinylbenzimidazoles
EP1601667A2 (en) * 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
JP4355703B2 (ja) * 2003-03-13 2009-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 歯ぎしりの予防剤または治療剤
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
US7524837B2 (en) * 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
EP1615913A2 (en) 2003-06-10 2006-01-18 Teva Pharmaceutical Industries Limited Process for preparing 2-(pyridinyl)methyl sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
AU2004264401A1 (en) * 2003-07-15 2005-02-24 Allergan, Inc. Process for preparing isomerically pure prodrugs of proton pump inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
WO2005074929A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
CA2556756A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
CA2557471A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
MXPA06009991A (es) * 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
AR048631A1 (es) * 2004-04-28 2006-05-10 Altana Pharma Ag Derivados de dialcoxi-imidazopiridinas, composiciones farmaceuticas que los contienen y usos,
EP1746980B1 (en) * 2004-05-07 2011-11-02 Nycomed GmbH Pharmaceutical dosage form comprising pellets as well as its manufacturing process
TW200613301A (en) * 2004-06-15 2006-05-01 Altana Pharma Ag Novel amino-halogen-imidazopyridines
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
EP1814591A4 (en) 2004-11-22 2009-04-22 Anadis Ltd BIOACTIVE PREPARATIONS
AU2005315390B2 (en) * 2004-12-16 2011-10-27 Cipla Limited Process for the preparation of pantoprazole sodium
WO2007036771A2 (en) * 2005-05-06 2007-04-05 Medichem, S.A. Pantoprazole free acid form iii
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
EP1747776A1 (en) 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
WO2007026188A1 (en) * 2005-09-01 2007-03-08 Wockhardt Limited Process for the manufacture of antiulceratives
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5053865B2 (ja) 2005-12-28 2012-10-24 武田薬品工業株式会社 口腔内崩壊性固形製剤の製造法
WO2007086077A2 (en) * 2006-01-24 2007-08-02 Unichem Laboratories Limited A novel one pot process for preparation of pantoprazole sodium sesquihydrate
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
US20090111856A1 (en) * 2006-05-09 2009-04-30 Mikael Brulls Parenteral Formulation Comprising Proton Pump Inhibitor Sterilized in its Final Container by Ionizing Radiation
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007146341A2 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of pantoprazole magnesium salt
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP3628307A1 (en) 2006-12-22 2020-04-01 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
KR20090121388A (ko) * 2007-03-15 2009-11-25 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 전구약물
EP2181106A1 (en) * 2007-07-17 2010-05-05 Ranbaxy Laboratories Limited Process for the preparation op pantoprazole sodium and pantoprazole sodium sesquihydrate
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
WO2010029335A1 (en) 2008-09-09 2010-03-18 Astrazeneca Uk Limited Method for delivering a pharmaceutical composition to patient in need thereof
WO2010042785A1 (en) * 2008-10-10 2010-04-15 Celtaxsys, Inc. Method of inducing negative chemotaxis
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
WO2010151697A1 (en) * 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
BR112015016917B1 (pt) 2013-01-15 2022-08-30 Ironwood Pharmaceuticals, Inc Forma de dosagem oral de retenção gástrica, e, uso de um sequestrante de ácido biliar
WO2014160405A1 (en) * 2013-03-13 2014-10-02 University Of Iowa Research Foundation Compounds, compositions comprising same, and methods related thereto
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
CN110487918B (zh) * 2018-05-14 2022-02-08 中国医学科学院药物研究所 泮托拉唑钠及其起始原料中基因毒性杂质的分析方法
WO2021061991A1 (en) 2019-09-24 2021-04-01 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
EP4204422A1 (en) 2020-08-26 2023-07-05 Syngenta Crop Protection AG Process for the preparation of 2,2-difluoro-1,3-benzodioxole derivatives with sulfur containing substituents
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234058A (cg-RX-API-DMAC7.html) * 1968-10-21 1971-06-03
PH16240A (en) * 1978-04-11 1983-08-11 Smith Kline French Lab Process for making histamine antagonist
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
IL66340A (en) * 1981-08-13 1986-08-31 Haessle Ab Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
IL71664A (en) * 1983-05-03 1987-11-30 Byk Gulden Lomberg Chem Fab Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same
IL71665A (en) * 1983-05-03 1988-05-31 Byk Gulden Lomberg Chem Fab Fluoro-(2-pyridyl-methylthio)-dioxolo-(and dioxino-)benzimidazoles,processes for their preparation and pharmaceutical compositions containing the same
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
DK170440B1 (da) 1995-09-04
CA1254215A (en) 1989-05-16
DE19475025I2 (de) 2009-01-02
IE851478L (en) 1985-12-16
AU578703B2 (en) 1988-11-03
PT80641B (de) 1987-04-28
SK278401B6 (en) 1997-04-09
MY103021A (en) 1993-04-30
BG61322B2 (bg) 1997-05-30
PT80641A (de) 1985-07-01
LU88700I2 (fr) 1996-04-29
IL75400A0 (en) 1985-10-31
EP0166287B1 (de) 1989-08-23
ES8705875A1 (es) 1987-06-01
PH23729A (en) 1989-11-03
NL950030I2 (nl) 1996-12-02
PH21850A (en) 1988-03-25
DE3572488D1 (en) 1989-09-28
IE58117B1 (en) 1993-07-14
CZ281242B6 (cs) 1996-07-17
DK268285D0 (da) 1985-06-13
ES544204A0 (es) 1987-06-01
CS396491A3 (en) 1992-09-16
CY1670A (en) 1993-10-10
AU4364085A (en) 1985-12-19
NZ212415A (en) 1989-03-29
HK86894A (en) 1994-09-02
NL950030I1 (cg-RX-API-DMAC7.html) 1996-02-01
US4758579A (en) 1988-07-19
EP0166287A1 (de) 1986-01-02
GR851399B (cg-RX-API-DMAC7.html) 1985-11-25
DK268285A (da) 1985-12-17
SG80192G (en) 1992-12-04

Similar Documents

Publication Publication Date Title
IL75400A (en) Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IL71310A0 (en) Benzimidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL83467A0 (en) Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
IL78111A0 (en) Sulfur-containing 5-substituted benzimidazole derivatives,their preparation and pharmaceutical compositions containing them
IL81172A0 (en) N-containing fused heterocyclic compounds,processes for the preparation thereof and pharmaceutical compositions comprising the same
AU7227587A (en) Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
IL96019A0 (en) Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL75120A0 (en) New pyrrolobenzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing them
IL80670A (en) Bicyclic sulfonamide derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
ZA859756B (en) Peptide-aldehydes,process for the preparation thereof and pharmaceutical compositions containing the same
IL83892A0 (en) (1h-imidazol-1-ylmethyl)substituted benzimidazole derivatives,their preparation and pharmaceutical compositions containing them
IL72085A0 (en) 13alpha-alkylylgonanes,processes for their preparation and pharmaceutical compositions containing the same
IL84446A0 (en) 3-pyrrolidinylthio-1-azabicyclo-(3.2.0)hept-2-ene-2-carboxylic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL81950A0 (en) 2-azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof processes for the preparation thereof and pharmaceutical compositions containing them
IL83760A (en) 3-pyrazoliomethyl-3- cephem-4-carboxylate derivatives, process for the preparation thereof, and pharmacetuical compositions containing the same
IL84589A0 (en) Pyrrolobenzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing them
IL92425A0 (en) Alpha-d-glucofuranose derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
IL62039A0 (en) Imidazoline derivative,processes for the preparation thereof and pharmaceutical compositions containing the same
IL84913A0 (en) Alkanesulfonanilide derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
IL73840A0 (en) 5-pyrimidinecarboxamides and thiocarboxamides,processes for the preparation thereof and pharmaceutical compositions containing the same
IL88903A (en) Indolylpiperidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL87563A0 (en) Isoxazole-beta-carboline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL78576A0 (en) 5-pyrimidinecarboxamide,processes for the preparation thereof and pharmaceutical compositions containing same
IL70488A0 (en) Fluoromethylthiooxacephalosporins,processes for the preparation thereof and pharmaceutical and veterinary compositions containing the same
IL64880A0 (en) Imidazoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
EXP Patent expired